Can­cer biotech ends tri­al, search­es for sale or oth­er route

Aileron Ther­a­peu­tics has scrapped its tri­al, laid off most em­ploy­ees and is search­ing for a merg­er part­ner or oth­er strate­gic al­ter­na­tive.

The Boston biotech said a re­view of ini­tial da­ta from a Phase Ib tri­al showed pa­tients “ex­pe­ri­enced se­vere neu­trope­nia (Grade 4) and alope­cia,” com­mon­ly known as hair loss. Aileron was test­ing its drug AL­RN-6924 in pa­tients with p53-mu­tat­ed breast can­cer. The open-la­bel study was test­ing neoad­ju­vant or ad­ju­vant treat­ment with do­c­etax­el, dox­oru­bicin, and cy­clophos­phamide, al­so known as “TAC” chemother­a­py.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.